Dl. Medina et al., Somatostatin is expressed in FRTL-5 thyroid cells and prevents thyrotropin-mediated down-regulation of the cyclin-dependent kinase inhibitor p27(kip1), ENDOCRINOL, 140(1), 1999, pp. 87-95
Using RT and amplification, we have detected specific RNA transcripts encod
ing somatostatin in FRTL-5 thyroid cells. This observation indicates that w
ithin the thyroid context, expression of somatostatin is not restricted to
the parafollicular C cells. Transfection of FRTL-5 cells with constructs co
ntaining either the complete somatostatin gene promoter or deletions carryi
ng the cAMP response element-binding site allowed us to demonstrate that tr
anscription of the somatostatin gene is hormonally regulated by TSH. Blocka
ge of somatostatin by specific antibodies resulted in an increased capacity
of TSH-induced FRTL-5 cell-conditioned medium to promote cell proliferatio
n, demonstrating that under physiological conditions, somatostatin exerts a
cytostatic effect on FRTL-5 cells growth. Somatostatin treatment of FRTL-5
cells resulted in a growth retardation, caused by a dose-response delay in
the G(1) phase of the cell cycle. This effect appears to be mediated by th
e cyclin-dependent kinase inhibitor p27(kip1), which is clearly down-regula
ted in FRTL-5 cells treated with TSH and whose expression is reestablished
by somatostatin in a dose-dependent manner. Participation of somatostatin i
n the control of FRTL-5 cell proliferation is in agreement with the detecti
on of specific somatostatin receptor type 2. Flow cytometric assays reveal
that FRTL-5 cells transformed with the K-ras oncogene are still sensitive t
o somatostatin treatment, whereas fully neoplastic FRT cells no longer resp
ond to this peptide. Taking together, the results demonstrate the participa
tion of an autocrine loop in the control of thyroid cell proliferation, and
the possibility that this mechanism could be altered in the process of thy
roid carcinogenesis.